Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-Lung: Tislelizumab + Chemotherapy + BACE for Unresectable NSCLC
NCT07561983Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Event-Free Survival Rate at 1 year. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07561983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561983.